Analyst coverage
Small Pharma is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Small Pharma’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Small Pharma or its management. Small Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
A pipeline of short duration psychedelic programs
Our pipeline targets the development of treatments that provide fast-acting and long-lasting relief, and have in-clinic scalability potential to address the growing mental health crisis.
Years of R&D development
Number of granted patents
CAD$ raised in 2021
Leadership team
Latest press releases
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Results suggest SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a…
Cybin to Acquire Small Pharma Inc.
Cybin to acquire Small Pharma creating an international clinical-stage leader in novel psychedelic therapeutics.
Small Pharma Reports Fiscal First Quarter 2024 Highlights
Financial highlights and recent business and R&D highlights.
Events & conferences
Join us at our upcoming events and conferences online and around the globe. Register today or review our library of past events.